| Thursday | ||||
Cantor Fitzgerald analyst… Cantor Fitzgerald analyst Brandon Folkes raised the firm's price target on Emergent BioSolutions to $55 from $50 and keeps an Overweight rating on the shares. The price target revision is driven by marginally increased visibility on the company's longer-term topline growth profile, and as well as a greater appreciation for near-term cash generation, Folkes tells investors in a research note. At the same time, the analyst believes that the 2022 guidance is not an all clearing event for the overhangs that remain. | ||||
Benchmark analyst Robert… Benchmark analyst Robert Wasserman upgraded Emergent BioSolutions to Buy from Hold with a $77 price target, which represents 60% appreciation from the current share price. He cites what he views as an improved outlook for 2022, including an expected rebound in contract development and manufacturing revenues and a "brighter" short-term outlook for nasal naloxone product sales following a milder generic launch. | ||||
| Over a week ago | ||||
Emergent BioSolutions… Emergent BioSolutions announced that Fuad El-Hibri, founder and executive chairman, has decided to retire effective April 1. Given El-Hibri's wisdom, knowledge, experience, and history with the company, Emergent anticipates that El-Hibri will still be available as needed to effectively transition his knowledge to the Board of Directors and management team. The details of any arrangement related to that are under consideration by the Emergent Board of Directors and will be disclosed when approved by the Board. Emergent expects to name a new Chair of the Board of Directors ahead of El-Hibri's retirement. | ||||
Emergent BioSolutions… Emergent BioSolutions reported preliminary 2021 total revenues of $1.78 billion at the midpoint and Adjusted EBITDA of $513 million, or 29%, at the midpoint, both in line with prior guidance given in November 202. The company expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45 billion at the midpoint and Adjusted EBITDA margin of 21.5% at the midpoint. | ||||
Cowen analyst Boris… Cowen analyst Boris Peaker keeps a Market Perform rating on Emergent BioSolutions with a $67 price target after the company reported that a generic naloxone has entered the market. The generic entry timing is earlier than expected, says the analyst, who anticipates revenue and margin erosion for Emergent over the next several years. Peaker thinks the company's authorized generic with Sandoz "is unlikely to help much" and that Narcan sales will be threatened "immediately." | ||||
| Over a month ago | ||||
Emergent BioSolutions… Emergent BioSolutions announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company's investigational universal influenza vaccine candidate. This current version of Emergent's universal influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses. "Emergent remains focused on investing in our diverse portfolio of R&D programs targeting infectious disease and other public health threats," said Kelly Warfield, Ph.D., senior vice president, research and development at Emergent BioSolutions. "Initiating this phase 1 study demonstrates our commitment to advancing our pipeline and our research and development team's scientific prowess to adopt an innovative technology and investigate a potential vaccine candidate for a disease that affects millions every year." The goal of this single-center, randomized, double blind, placebo-controlled dose-escalation study is to evaluate the safety, tolerability, and immunogenicity of the vaccine candidate at two dose levels and two schedules in 60 healthy adult individuals aged 18 to 45. This phase 1 study, being conducted in Australia, is fully funded by Emergent. | ||||
SMid Cap Biotech Analyst… SMid Cap Biotech Analyst Fye holds a conference call with CEO Kramer and CFO Lindahl on December 1 at 2 pm hosted by JPMorgan. | ||||
SMid Cap Biotech Analyst… SMid Cap Biotech Analyst Fye holds a conference call with CEO Kramer and CFO Lindahl on December 1 at 2 pm hosted by JPMorgan. | ||||
SMid Cap Biotech Analyst… SMid Cap Biotech Analyst Fye holds a conference call with CEO Kramer and CFO Lindahl on December 1 at 2 pm hosted by JPMorgan. | ||||
Paper Excellence B.V. is… Paper Excellence B.V. is acquiring Domtar in a deal expected to be completed soon pending final conditions. | ||||
